Oncolytics Biotech (ONCY) Beginning Cash Balance (2009 - 2025)

Oncolytics Biotech (ONCY) has reported Beginning Cash Balance for 17 consecutive years, with $11.1 million the latest figure, recorded in Q1 2025.

• In Q1 2025, Beginning Cash Balance fell 57.12% year-over-year to $11.1 million; the TTM figure through Sep 2025 stood at $11.1 million (down 57.12% YoY), while the FY2024 annual figure was $25.5 million, up 194.92% from the prior year.
• Beginning Cash Balance fell to $11.1 million in Q1 2025 per ONCY's latest filing, from $25.9 million in the prior quarter.
• Across five years, Beginning Cash Balance topped out at $41.0 million in Q2 2021 and bottomed at $337.96 in Q4 2021.
• Historically, Beginning Cash Balance has averaged $23.9 million across 5 years, with a median of $25.9 million in 2024.
• Annual changes were most pronounced in 2021 — Beginning Cash Balance surged 2198.08% — and 2023, when it sank 73.51%.
• Oncolytics Biotech's Beginning Cash Balance stood at $337.96 in 2021, then jumped by 9163124.05% to $31.0 million in 2022, then plunged by 72.13% to $8.6 million in 2023, then jumped by 200.24% to $25.9 million in 2024, then plunged by 57.12% to $11.1 million in 2025.
• Business Quant data shows ONCY's Beginning Cash Balance at $11.1 million in Q1 2025, $25.9 million in Q1 2024, and $8.6 million in Q1 2023.